




**UNIVERSITÄTS  
KLINIKUM** **FREIBURG**

**CCCF** COMPREHENSIVE CANCER CENTER FREIBURG



**3<sup>rd</sup>**  **INTERNATIONAL  
LIQUID BIOPSY  
SYMPOSIUM**  
**FREIBURG 2020 – VIRTUAL**

**OCTOBER 30<sup>TH</sup> 2020**

**ONLINE SYMPOSIUM**



[www.uniklinik-freiburg.de/liquid-biopsy-symposium](http://www.uniklinik-freiburg.de/liquid-biopsy-symposium)

# Teaming up to deliver a truly comprehensive and dynamic picture of cancer

The AVENIO family of NGS oncology assays combine the benefits of monitoring using ultra-sensitive liquid biopsies with gold-standard tumor profiling. Detect SNVs, indels, CNVs and fusions with exceptional sensitivity and specificity\* using a single end-to-end workflow. These ready-to-use kits are a versatile solution for labs interested in conducting comprehensive genomic profiling of solid tumors using plasma or tissue.


Go beyond disease-specific assays with the AVENIO oncology assays for a truly comprehensive and dynamic picture of solid tumors.



## The AVENIO family of NGS oncology assays

Three liquid biopsy and three corresponding tissue assays with exactly-matched panels

<b>Targeted Kit</b>	17 genes	Plasma or Tissue
<b>Expanded Kit</b>	77 genes	Plasma or Tissue
<b>Surveillance Kit</b>	197 genes	Plasma or Tissue



**Team up with Roche, your trusted partner in oncology.**

Contact your Roche representative today.

[sequencing.roche.com/avenio](https://sequencing.roche.com/avenio)

\*Data on file.

AVENIO is a trademark of Roche.

© 2020 Roche Sequencing Solutions, Inc. All rights reserved.

# 3<sup>rd</sup> INTERNATIONAL LIQUID BIOPSY SYMPOSIUM

The **3<sup>rd</sup> International Liquid Biopsy Symposium** will cover new technical developments and the latest advances in Liquid Biopsies. It will focus on how these might be translated to the clinic, how they can help better understand the underlying biology of malignant diseases, and how they can enhance the management of cancer patients in clinical routine.

We invite you to join internationally recognized experts in the field of Liquid Biopsy. This meeting is a unique opportunity to exchange ideas, discuss your latest research, and start collaborations with other clinicians, basic scientists, and translational researchers.

## The following topics will be covered:

- Early detection and screening
- Noninvasive genotyping and characterization of clonal heterogeneity
- Promoting Liquid Biopsies from bench to bedside
- Emerging Liquid Biopsy technologies and other liquids
- Noninvasive monitoring and resistance detection
- Circulating tumor cells (CTC) and CTC cultures
- Liquid Biopsy in Hematology

Due to the coronavirus pandemic, the Liquid Biopsy Symposium 2020 will be held as a virtual meeting facilitating online live presentations and discussions.

## SCIENTIFIC COMMITTEE:

Florian Scherer | University of Freiburg, Germany

Florence Schaffner | Cancéropôle Est, Strasbourg, France

Jean-Louis Merlin | University of Lorraine, Nancy, France

Julius Wehrle | University of Freiburg, Germany

Justus Duyster | University of Freiburg, Germany

# PROGRAM

## WELCOMING INTRODUCTION

**09.00 am** **Justus Duyster** | University of Freiburg, Germany  
**Florian Scherer** | University of Freiburg, Germany

## SESSION 1:

**09.15 am – 10.05 am** **NONINVASIVE GENOTYPING AND ASSESSMENT OF CLONAL HETEROGENEITY**

**On-site chairs:** Florian Scherer / Florence Schaffner  
**Virtual chairs:** Chris Abbosh / Catherine Alix-Panabières

**09.15 am** **Molecular diagnosis and monitoring of B-cell Non-Hodgkin lymphomas using cell-free DNA**

**Roland Schmitz** | University of Gießen/Marburg, Germany

**09.35 am** **Tissue-agnostic molecular risk stratification of ALK-mutated lung cancer patients**

**Holger Sültmann** | University of Heidelberg, DKFZ, Germany

**09.55 am** **Targeted next-generation sequencing enables ultra-sensitive detection of myxoid liposarcoma DNA - implications for routine diagnostic use of liquid biopsy**

**Anja Eisenhardt** | University of Freiburg, Germany

## SESSION 2:

**10.05 am – 10.55 am** **NONINVASIVE TUMOR MONITORING AND DETECTION OF RESISTANCE MECHANISMS**

**On-site chairs:** Florian Scherer / Florence Schaffner  
**Virtual chairs:** Chris Abbosh / Catherine Alix-Panabières

**10.05 am** **Early prediction of response in GIST, melanoma, and lung cancer**

**Nikolas von Bubnoff** | University of Lübeck, Germany

**10.25 am** **ctDNA to detect treatment resistance in metastatic breast cancer: PADA-1 and MONDRIAN trial**

**Jean-Yves Pierga** | Institut Curie Paris, France

**10.45 am** **Circulating free DNA combined to magnetic resonance imaging for early detection of HCC in patients with liver cirrhosis**

**Osman Oecal** | Ludwig-Maximilians-University of Munich, Germany

**10.55 am - 11.25 am** **BREAK**

### SESSION 3:

11.25 am –  
12.05 pm

#### PROMOTING LIQUID BIOPSY FROM BENCH TO BEDSIDE

**On-site chairs:** Julius Wehrle / Jean-Louis Merlin

**Virtual chairs:** Nikolas von Bubnoff / Holger Sültmann

11.25 am

#### Liquid Biopsy: From concept to clinical application

Catherine Alix-Panabières | University of Montpellier, France

11.45 am

#### A NGS-based blood test for the diagnosis of invasive HPV-associated carcinomas with extensive viral genomic characterizations

Alexandre Harlé | University of Lorraine, Nancy, France

### SESSION 4:

12.05 pm –  
01.35 pm

#### EMERGING TECHNOLOGIES AND OTHER LIQUIDS

**On-site chairs:** Julius Wehrle / Jean-Louis Merlin

**Virtual chairs:** Nikolas von Bubnoff / Holger Sültmann

12.05 pm

#### ctDNA in plasma and cerebrospinal fluid in glioblastoma patients

Christian Thiede | University of Dresden, Germany

12.25 pm

#### Extracellular vesicles in liquid biopsy

Irina Nazarenko | University of Freiburg, Germany

12.45 pm

#### Circulating exosomes to monitor tumor response in cancer patients

Jessica Gobbo | Dijon Cancer Center, France

01.05 pm

#### Liquid profiling of head and neck cancer patients in blood and saliva

Christof Winter | Technical University Munich, Germany

01.25 pm

#### Ral GTPases promote metastasis by controlling biogenesis and organ colonization of exosomes

Jacky Goetz | INSERM - Tumor Biomechanics, France

01.35 pm –  
02.15 pm

BREAK

02.15 pm –  
03.00 pm

**KEYNOTE LECTURE** Chairs: Florence Schaffner / Julius Wehrle

Nickolas Papadopoulos | Johns Hopkins University, Baltimore, USA

### SESSION 5:

03.00 pm –  
03.50 pm

#### LIQUID BIOPSY FOR EARLY CANCER DETECTION AND SCREENING

**On-site chairs:** Florence Schaffner / Julius Wehrle

**Virtual chairs:** Nickolas Papadopoulos / Alexandre Harlé

03.00 pm

#### Early detection of recurrence after surgery: TRACERx, MRD and adjuvant trials

Chris Abbosh | University College London, UK

03.20 pm **Molecular characterization of circulating tumor cells in lung cancer**  
Francesca Chemi | CRUK Manchester, UK

03.40 pm **SNiPER - liquid biopsy based early breast cancer detection using  
hypermethylation biomarkers**  
Jolein Mijnes | University Hospital RWTH Aachen, Germany

03.50 pm -  
04.10. pm  
BREAK

04.10 pm –  
04.55 pm **KEYNOTE LECTURE** Chairs: Jean-Louis Merlin / Florian Scherer  
**Liquid Biopsy in hematology**  
Ash A. Alizadeh | Stanford University, USA

### **SESSION 6:**

04.55 pm –  
05.45 pm **LIQUID BIOPSY IN HEMATOLOGY**  
On-site chairs: Jean-Louis Merlin / Florian Scherer  
Virtual chairs: Ash A. Alizadeh / Roland Schmitz

04.55 pm **Qualification and quantification of lymphoma under therapy by ctDNA analysis**  
Davide Rossi | Institute of Oncology Research, Bellinzona, Switzerland

05.15 pm **Liquid Biopsy in Hodgkin Lymphoma for genotyping, biological risk stratification  
and detection of minimal residual disease**  
Sven Borchmann | University of Cologne, Germany

05.35 pm **Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes  
in circulating cell-free DNA in patients with acute Graft-versus-Host disease**  
Jesús Duque-Afonso | University of Freiburg, Germany

05.45 pm –  
06.00 pm CLOSING REMARKS

## **REGISTRATION IS FREE**

For registration and abstract submission please use the following link:

[www.uniklinik-freiburg.de/liquid-biopsy-symposium](http://www.uniklinik-freiburg.de/liquid-biopsy-symposium)

# SPONSORS

## GOLDSPONSOR



## OTHERS



## DISCLOSURE OF SPONSORSHIPS

AMGEN GmbH – 1.000€ \*

Bristol –Myers Squibb GmbH & Co. KGaA – 750€\*

Roche Diagnostics Deutschland GmbH – 3.000€\*

\* for promotional purposes



FOUNDATIONONE® LIQUID CDx



JETZT  
VERFÜGBAR



# PERSONALISIERTE BEHANDLUNGS- MÖGLICHKEITEN MIT LIQUID BIOPSY

Die **zertifizierte** Liquid-Biopsy-Lösung bietet eine NGS-Analyse für alle Patienten mit soliden Tumoren. Die **minimalinvasive** Diagnostik kann als **Alternative** oder **komplementär** zur **Gewebeprobe** eingesetzt werden und die **Therapiefindung unterstützen**.<sup>1-3</sup>



[www.foundationmedicine.de](http://www.foundationmedicine.de)

CDx: companion diagnostic.

1. FoundationOne®Liquid CDx Technical Specifications, 2020. Abrufbar unter: [www.eifu.online/FMI/190070862](http://www.eifu.online/FMI/190070862) (Zugriff: September 2020). 2. Woodhouse R et al. PLoS ONE 2020; 15(9): e0237802. 3. FoundationOne®Liquid CDx FDA Approval, 2020. Abrufbar unter: <https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721> (Zugriff: September 2020).

© 2018 Foundation Medicine, Inc. Foundation Medicine®, FoundationOne®CDx und FoundationOne®Liquid CDx sind eingetragene Warenzeichen. Roche ist der lizenzierte Anbieter von Foundation Medicine®-Produkten außerhalb der Vereinigten Staaten von Amerika.

Mehr erkennen,  
besser behandeln.



FOUNDATION  
MEDICINE®

Roche